#Biogen

@biznizinsiderph.bsky.social

1 month ago

Three years after its first launch in the US, there are signs that #Biogen and #Eisai's #Alzheimer's #Leqembi therapy is gathering sales momentum.

pharmaphorum.com/news/leqembi...

0 0 0 0

Bizniz Insider PH

1 month ago

New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits - AktieGo BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI ...

Eisai and Biogen are developing a new version of their Alzheimer’s drug, LEQEMBI IQLIK, that patients could inject at home. The FDA has accepted it for Priority Review, with a decision expected in May 2026.

aktiego.com/new-leqembi-...

#Alzheimers #Healthcare #Biogen #Eisai #Pharma

0 0 0 0

INFORMED

@wetestyoutrust.bsky.social

2 months ago

Something big is coming.

22.01.2026

Stay tuned to our Informed Sport partner Biogen next Thursday for an exciting announcement!

#WeTestYouTrust #InformedSport #Biogen #ComingSoon

1 0 0 0

Proximity Health Solutions and Biogen Selected as Finalists for '26 SCOPE Engagement Award Proximity Health Solutions and Biogen have been recognized as finalists for the prestigious SCOPE '26 Participant Engagement Award for their impactful lupus webinar series.

2 months ago

Proximity Health Solutions and Biogen Selected as Finalists for '26 SCOPE Engagement Award #USA #Stamford #Biogen #Better_Together #Lupus_Warrior

0 0 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

2 months ago

NICE recommends wider use of Biogen MS drug via NHS NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

#neurology #NICE #Biogen #natalizumab #Tysabri #multiplesclerosis #MS #activerelapsingremittingmultiplesclerosis #biosimilar #NICEdraftguidance #Sandoz #PolpharmaBiologics #biosimilarequivalent #Tyruko #activerelapsingremittingMS #rapidlyevolvingsevereMS #biosimilarmedicines
zurl.co/tsiGu

0 0 0 0

Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders - Vanqua Bio CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, wh...

3 months ago

#Biogen is facing #biosimilar competition to its big-selling #multiplesclerosis therapy Tysabri in the US for the first time, as #Sandoz enters the market.

pharmaphorum.com/news/sandoz-...

0 0 0 0

Lee Doza

@lorion70.bsky.social

4 months ago

Meanwhile, #Accenture Labs, biotechnology firm #Biogen and quantum computing company #1QBit are collaborating on research related to #drugdiscovery. Quantum computers can compare molecules that are much larger than the ones classical computers can compute, Accenture said on its website.

2 1 1 0

Gilbert Gerber

@giger1964.bsky.social

4 months ago

www.vanquabio.com/vanqua-bio-t...
Looking for this #C5aR1 data. If you attended, could you please share ?
#VanquaBio #InflaRx $IFRX #Biogen $BIIB

0 0 0 0

STAT

@handle.invalid

4 months ago

At a gathering of biopharma executives, a moment of wonder — and also of worry Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a pharma CEO and a toddler in a tuxedo.

0 0 0 0

STAT

@handle.invalid

4 months ago

At a gathering of biopharma executives, a moment of wonder — and also of worry Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a pharma CEO and a toddler in a tuxedo.

0 0 0 0

Neuromuscular Disease Therapeutics Market's Surge to $45.62 Billion by 2033 Fueled by Innovative Treatments The Neuromuscular Disease Therapeutics Market is projected to soar to $45.62 billion by 2033, driven by groundbreaking advancements in gene therapies and RNA-based treatments.

5 months ago

Neuromuscular Disease Therapeutics Market's Surge to $45.62 Billion by 2033 Fueled by Innovative Treatments #United_States #Austin #Biogen #Neuromuscular #gene_therapies

0 0 0 0

@pharmalot.bsky.social

5 months ago

Pharmalittle: We're reading about Novo Nordisk layoffs, an Amgen discount program, and more In today's Pharmalittle roundup, we're reading about Novo Nordisk layoffs, an Amgen discount program, and more.

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Novo Nordisk layoffs, an Amgen discount program & much more news.. statnews.com/pharmalot/20... #pharma #Medicare #obesity #weight #patents #layoffs #medicine #Amgen #Gilead #AstraZeneca #NovoNordisk #Biogen #Roche

0 0 0 0

Eisai and Biogen Unveil New Approach to Early Alzheimer's Treatment Via LEQEMBI® IQLIK™ Injection Eisai and Biogen have launched LEQEMBI® IQLIK™, a new at-home treatment option for early Alzheimer's that enhances patient support during therapy.

5 months ago

Eisai and Biogen Unveil New Approach to Early Alzheimer's Treatment Via LEQEMBI® IQLIK™ Injection #United_States #Cambridge #Eisai #Biogen #LEQEMBI®

0 0 0 0

Biogen buys CNS delivery specialist Alcyone Therapeutics Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

5 months ago

#Biogen has reached a deal to buy #AlcyoneTherapeutics, a privately held company that has developed a system for delivering antisense oligonucleotides (#ASOs) directly into the #centralnervoussystem.

0 0 0 0

Sociedad Española de Bioquímica y Biología Molecular (SEBBM)

@sebbm.bsky.social

6 months ago

Irene Aranda Carrillo - Conferencia Biogen Científica
Modera: María Monsalve

#conferenciapatrocinadores #47congresosebbm #biogen

1 0 0 0

6 months ago

#Eisai and #Biogen have won FDA approval for a #subcutaneous injection version of Leqembi that could help accelerate uptake of the #Alzheimers disease therapy.

pharmaphorum.com/news/dose-ho...

0 0 0 0